List of Sponsors

For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.

Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy. Our mission is to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines. Built on our proprietary ImmTAX technology, we have a pipeline of investigational bispecific TCR therapies across a broad range of diseases, including multiple types of cancers, HIV, HBV, type 1 diabetes, and other autoimmune diseases.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Pierre Fabre is a French pharmaceutical and dermo-cosmetic laboratory, with 35-year experience in innovation, development, manufacturing and commercialization in oncology. The Group recently reaffirmed that oncology is one of its priorities in R&D and from a business perspective, focusing on targeted therapies, biotherapies and immuno-oncology. Its scope of therapeutic activity covers medical niches for which it does not exist treatment, such as colorectal, breast, lung cancers, melanoma and precancerous conditions as actinic keratosis. Pierre Fabre‘s expertise in dermatology, combined with its knowledge in the field of oncology, puts the company in a unique position to fight against skin cancers from multiple angles.

In 2019, Pierre Fabre generated 2.4 billion euros in revenues, of which two-thirds originated from its international business. Pierre Fabre, which has always been headquartered in the South-West of France, employs approximately 10,500 people worldwide, owns subsidiaries and offices in 45 countries and enjoys distribution agreements in over 130 countries. Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation since 1999, and secondarily by its own employees through an international employee stock ownership plan.

Learn more at www.pierre-fabre.com.